• Je něco špatně v tomto záznamu ?

Vancomycin loading dose individualization in a population of obese patients undergoing haemodialysis based on population pharmacokinetic model

L. Polášková, JM. Hartinger, I. Murínová, P. Michálek, O. Slanař, M. Šíma

. 2025 ; 37 (2) : 121-129. [pub] 20240617

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009405

This study aimed to develop a vancomycin population pharmacokinetic model in obese adult patients treated with intermittent haemodialysis and propose a model-based loading dose strategy ensuring attainment of newly recommended AUC-based PK/PD target. Retrospective cross-sectional analysis was performed among obese haemodialysis dependent adult patients treated with intravenous vancomycin. A pharmacokinetic population model was developed using a nonlinear mixed-effects modelling approach and Monte Carlo simulations were used to identify the optimal loading dose for PK/PD target attainment during the first 48 h of treatment. Therapeutic drug monitoring data from 27 patients with a BMI of 30.2-52.9 kg/m2 were analysed. Among all tested variables, only LBM as a covariate of vancomycin Vd significantly improved the model, while vancomycin CL did not correlate with any of the tested variables. The median (IQR) value from the conditional mean of individual estimates of Vd and CL was 68.4 (56.6-84.2) L and 0.86 (0.79-0.90) L/h, respectively. To ensure optimal vancomycin exposure during the first 48 h of therapy, the vancomycin loading dose of 1500, 1750, 2000, 2250, 2500 and 2750 mg should be administered to obese patients with a lean body mass of ˂50, 50-60, 60-70, 70-80, 80-85 and >85 kg, respectively.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009405
003      
CZ-PrNML
005      
20250429135256.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/1120009X.2024.2367937 $2 doi
035    __
$a (PubMed)38887026
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Polášková, Lucie $u Department of Clinical Pharmacy, Military University Hospital Prague, Prague, Czech Republic
245    10
$a Vancomycin loading dose individualization in a population of obese patients undergoing haemodialysis based on population pharmacokinetic model / $c L. Polášková, JM. Hartinger, I. Murínová, P. Michálek, O. Slanař, M. Šíma
520    9_
$a This study aimed to develop a vancomycin population pharmacokinetic model in obese adult patients treated with intermittent haemodialysis and propose a model-based loading dose strategy ensuring attainment of newly recommended AUC-based PK/PD target. Retrospective cross-sectional analysis was performed among obese haemodialysis dependent adult patients treated with intravenous vancomycin. A pharmacokinetic population model was developed using a nonlinear mixed-effects modelling approach and Monte Carlo simulations were used to identify the optimal loading dose for PK/PD target attainment during the first 48 h of treatment. Therapeutic drug monitoring data from 27 patients with a BMI of 30.2-52.9 kg/m2 were analysed. Among all tested variables, only LBM as a covariate of vancomycin Vd significantly improved the model, while vancomycin CL did not correlate with any of the tested variables. The median (IQR) value from the conditional mean of individual estimates of Vd and CL was 68.4 (56.6-84.2) L and 0.86 (0.79-0.90) L/h, respectively. To ensure optimal vancomycin exposure during the first 48 h of therapy, the vancomycin loading dose of 1500, 1750, 2000, 2250, 2500 and 2750 mg should be administered to obese patients with a lean body mass of ˂50, 50-60, 60-70, 70-80, 80-85 and >85 kg, respectively.
650    _2
$a lidé $7 D006801
650    12
$a vankomycin $x farmakokinetika $x aplikace a dávkování $7 D014640
650    12
$a dialýza ledvin $7 D006435
650    12
$a obezita $x komplikace $7 D009765
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a antibakteriální látky $x farmakokinetika $x aplikace a dávkování $7 D000900
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a průřezové studie $7 D003430
650    _2
$a senioři $7 D000368
650    _2
$a monitorování léčiv $7 D016903
650    _2
$a metoda Monte Carlo $7 D009010
650    _2
$a dospělí $7 D000328
650    _2
$a biologické modely $7 D008954
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hartinger, Jan Miroslav $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Murínová, Irena $u Department of Clinical Pharmacy, Military University Hospital Prague, Prague, Czech Republic $u Department of Applied Pharmacy, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic
700    1_
$a Michálek, Pavel $u Department of Anaesthesia and Intensive Care, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Slanař, Ondřej $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $1 https://orcid.org/0000000253577562 $7 xx0058262
700    1_
$a Šíma, Martin $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $1 https://orcid.org/000000026541738X $7 xx0222901
773    0_
$w MED00181505 $t Journal of chemotherapy $x 1973-9478 $g Roč. 37, č. 2 (2025), s. 121-129
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38887026 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135251 $b ABA008
999    __
$a ok $b bmc $g 2311033 $s 1246486
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 37 $c 2 $d 121-129 $e 20240617 $i 1973-9478 $m Journal of chemotherapy $n J Chemother $x MED00181505
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace